Double-Drug attack: new hope for stubborn IBD?
NCT ID NCT07660289
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This study looked at 117 people with inflammatory bowel disease (IBD) who were given a combination of two advanced drugs (either two biologics or one biologic plus a small molecule pill). The goal was to see if this dual approach works better and is safe in real-world clinics. Researchers tracked how many patients went into remission or avoided surgery within 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMBINATION THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hosipital of Digestive Disease
Xi'an, Shaanxi, 710005, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination of two biologic agents or one biologic plus one small molecule drug
What this could lead to
If successful, this could point toward more effective treatment options for people with hard-to-control IBD.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. The combination therapies also carry higher risks of side effects like infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.